 |
|
|
| |
Baseline Clinical and Laboratory Parameters Associated With Clinical Benefits of Successful HCV Treatment With Sofosbuvir/Velpatasvir in Decompensated Cirrhotic Patients
|
| |
| |
Reported by Jules Levin
EASL 2026 April 14-17 Barcelona
Jacqueline O'Leary,1 Robert S. Brown,2 K. Rajender Reddy,3 Jonathan Fenkel,4 Kevin Korenblat,5 Ziad H. Younes,6 Robert Herring,7 Di An,8 Anu Osinusi,8 John McNally,8 Diana M. Brainard,8 John G. McHutchison,8 Michael P. Curry,9 Michael Charlton10
1Baylor University Medical Center at Dallas, Texas, USA; 2Weill Cornell Medical College, New York, New York, USA; 3Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA; 4Thomas Jefferson University, Philadelphia, USA; 5Washington University School of Medicine in Saint Louis, Missouri, USA;
6Gastro One, Germantown, Tennessee, USA; 7Quality Medical Research, Nashville, Tennessee; 8Gilead Sciences, Inc., Foster City, California, USA; 9Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 10Intermountain Medical Center, Murray, Utah, USA
|
| |
|
|
|
|
|
